Clinical trials: Schizo Affective Disorder
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia.
- Trial name
- NCT00517075
- Testing
- Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Obesity, Schizophrenia
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
The purpose of this clinical trial is to find out how effective low dose oral naltrexone is on reducing body weight when compared to placebo in women with schizophrenia and schizoaffective disorder.
- Conditions
- Obesity, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00793780
- Testing
- Naltrexone 25mg
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Bipolar Disorder, Schizo Affective Disorder
Brain Stimulation and Cognitive Training
People with serious mental illness often report difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities.
- Conditions
- Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
- Trial name
- NCT03338673
- Testing
- tDCS, BrainHQ
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
- Trial name
- NCT00176423
- Testing
- galantamine
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse
- Trial name
- NCT00156715
- Testing
- Quetiapine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Pediatric
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT04779177
- Testing
- Lumateperone 42 mg, Lumateperone 28 mg
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers
Negative symptoms significantly interfere with daily functioning among individuals with schizophrenia. They are strongly related to functional impairments [1] and contribute to the poor community outcomes of Veterans with…
- Trial name
- NCT02386605
- Testing
- Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia, Schizoaffective Disorder
Antipsychotic Effects on Brain Function in Schizophrenia
The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- APD (NCT01913327)
- Testing
- Aripiprazole, Risperidone, Modafinil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Psychosis
The Family Cognitive Adaptation Training Manual: A Test of Effectiveness
The purpose of this study is to examine the effectiveness of family cognitive adaptation training, including its impact on functioning and caregiver burden.
- Trial name
- NCT01768000
- Testing
- Family Cognitive Adaptation Training
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia
This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia.
- Trial name
- NCT00406718
- Testing
- Med-eMonitor, PharmCAT, Treatment as Usual
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Insomnia, Schizophrenia
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life.
- Conditions
- Insomnia, Schizophrenia, Schizoaffective Disorder, Sleep Disorders
- Trial name
- NCT00645944
- Testing
- Eszopiclone
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
The study is a retrospective cohort study of adults with schizophrenia that will compare outcomes of new users of alternative psychotropic medication strategies using 10 years of Medicaid data.
- Trial name
- NCT02775864
- Testing
- Antipsychotic, Antidepressant, Benzodiazepine
- Volunteers
- 81,921 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently diagnosed with schizophrenia or schizoaffective disorder.
- Trial name
- NCT01929889
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University